Featured Publications
Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC.
Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm DL, Pusztai L. Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC. Clinical Cancer Research 2022, 28: 3720-3728. PMID: 35903931, PMCID: PMC9444984, DOI: 10.1158/1078-0432.ccr-22-0862.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsTriple-negative breast cancerNon-AA patientsEvent-free survivalPhase I/II clinical trialsClinical trialsNeoadjuvant chemotherapyOverall survivalAA patientsEarly-stage triple-negative breast cancerIncidence of irAEsPathologic complete response rateSignificant associationMultivariate logistic regression analysisTumor-infiltrating lymphocyte countsComplete response ratePrimary efficacy endpointPD-L1 statusProportional hazards modelLogistic regression analysisAfrican American womenEFS ratesNeoadjuvant immunotherapyEfficacy endpointAdverse eventsClinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancer
Silva S, Pereira A, Marta G, de Barros Lima K, de Freitas T, Matutino A, de Azevedo Souza M, de Azevedo R, de Viveiros P, da Silva Lima J, Filassi J, de Andrade Carvalho H, Piato J, Mano M. Clinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancer. The Breast 2017, 38: 39-44. PMID: 29223797, DOI: 10.1016/j.breast.2017.11.012.Peer-Reviewed Original ResearchConceptsPost-operative radiation therapyDisease-free survivalBetter disease-free survivalNeoadjuvant chemotherapyBreast cancerOverall survivalAdvanced breast cancerClinical stage IIIBetter overall survivalAdvanced BC patientsTherapy delayBC patientsClinical impactEarly initiationRadiation therapyStage IIIPatientsSurgeryOptimal timingWeeksChemotherapyFirm conclusionsCancerSurvivalInitiationIntratumour heterogeneity, from hypothesis to the clinic
Shan NL, Kahn A, Pusztai L. Intratumour heterogeneity, from hypothesis to the clinic. British Journal Of Cancer 2022, 128: 459-460. PMID: 36216884, PMCID: PMC9938204, DOI: 10.1038/s41416-022-02008-w.Commentaries, Editorials and LettersCDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
Matutino A, Amaro C, Verma S. CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease. Therapeutic Advances In Medical Oncology 2018, 10: 1758835918818346. PMID: 30619511, PMCID: PMC6299331, DOI: 10.1177/1758835918818346.Peer-Reviewed Original ResearchTriple-negative breast cancerProgression-free survivalBreast cancerCDK4/6 inhibitorsHormone receptor-positive HER2-negative diseaseCyclin-dependent kinase 4/6 inhibitorsPositive human epidermal growth factor receptor 2Human epidermal growth factor receptor 2Epidermal growth factor receptor 2HER2-negative diseaseGrowth factor receptor 2Metastatic breast cancer therapyNegative breast cancerBreast cancer therapyFactor receptor 2Preclinical evidenceClinical dataReceptor 2Later linesHormone receptorsCancerCancer therapyCell linesInhibitorsCDK inhibitorsThe impact of age in the quality of life of patients diagnosed with breast cancer after curative treatment.
Matutino A, Lewis J, Verma S, Taylor A, Huber S, Chen G. The impact of age in the quality of life of patients diagnosed with breast cancer after curative treatment. Journal Of Clinical Oncology 2018, 36: 67-67. DOI: 10.1200/jco.2018.36.7_suppl.67.Peer-Reviewed Original ResearchBreast cancerDifferent age groupsCurative treatmentAge groupsRetrospective cross-sectional analysisAnti-hormonal therapyBreast conserving surgeryCancer Patient QuestionnaireQuality of lifeImpact of ageCross-sectional analysisHigh financial burdenSurvivorship careConserving surgeryPatient questionnaireCurative therapySecond cancersLess painQOL scoresInvasive diseaseQoL dataHigh prevalenceStage 0Radiation therapyOngoing anxietyStrategies to mitigate the toxicity of cancer therapeutics
Kahn AM, Blenman KRM, Sonis ST, Lustberg MB. Strategies to mitigate the toxicity of cancer therapeutics. Advances In Cancer Research 2022, 155: 215-244. PMID: 35779875, DOI: 10.1016/bs.acr.2022.02.006.Peer-Reviewed Original ResearchConceptsAromatase inhibitor-induced musculoskeletal symptomsChemotherapy-induced peripheral neuropathyCancer-related cognitive impairmentCancer treatment symptomsOral mucosal toxicityImmune checkpoint inhibitionTyrosine kinase inhibitorsCancer therapeuticsGastrointestinal toxicityMucosal toxicityAdverse eventsHormone therapySystemic therapyTreatment toxicityPeripheral neuropathyCheckpoint inhibitionSymptom managementMusculoskeletal symptomsRenal toxicityTreatment symptomsOcular toxicityTreatment modalitiesTraditional chemotherapyCognitive impairmentMonoclonal antibodiesComparison of clinical characteristics and survival of metastatic breast cancer patients in United States according to insurance status as compared to outcomes in Canada.
Matutino A, Pereira A, Kornaga E, Lupichuk S, Verma S. Comparison of clinical characteristics and survival of metastatic breast cancer patients in United States according to insurance status as compared to outcomes in Canada. Journal Of Clinical Oncology 2018, 36: e18617-e18617. DOI: 10.1200/jco.2018.36.15_suppl.e18617.Peer-Reviewed Original ResearchIntratumor spatial heterogeneity in programmed death-ligand 1 (PD-L1) protein expression in early-stage breast cancer
Kahn A, Golestani R, Harigopal M, Pusztai L. Intratumor spatial heterogeneity in programmed death-ligand 1 (PD-L1) protein expression in early-stage breast cancer. Breast Cancer Research And Treatment 2023, 201: 289-298. PMID: 37378695, DOI: 10.1007/s10549-023-06977-1.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerPD-L1 expressionBreast cancerPD-L1Metastatic triple-negative breast cancerPD-L1 positive casesEarly-stage breast cancerPD-L1 protein expressionImmune checkpoint inhibitorsPD-L1 positivityPD-L1 statusProtein expressionWhole study populationPrimary breast tumorsNegative breast cancerConcordant negative resultsCheckpoint inhibitorsMultiple biopsiesPositive cancersCohen's kappa coefficientStudy populationE1L3N antibodyDiscordance rateBreast tumorsPositive casesOutcomes of acute pulmonary embolism in hospitalized patients with cancer.
Shalaby K, Kahn A, Silver ES, Kim MJ, Balakumaran K, Kim AS. Outcomes of acute pulmonary embolism in hospitalized patients with cancer. BMC Pulm Med 2022, 22: 11. PMID: 34986814, DOI: 10.1186/s12890-021-01808-9.Peer-Reviewed Original ResearchSurvival in Women with De Novo Metastatic Breast Cancer: A Comparison of Real-World Evidence from a Publicly-Funded Canadian Province and the United States by Insurance Status.
Savard MF, Kornaga EN, Kahn AM, Lupichuk S. Survival in Women with De Novo Metastatic Breast Cancer: A Comparison of Real-World Evidence from a Publicly-Funded Canadian Province and the United States by Insurance Status. Curr Oncol 2022, 29: 383-391. PMID: 35049708, DOI: 10.3390/curroncol29010034.Peer-Reviewed Original ResearchAseptic Meningitis as an Immune-Related Adverse Event after Pembrolizumab.
Lima G, Kahn A, Sama S, Savage J. Aseptic Meningitis as an Immune-Related Adverse Event after Pembrolizumab. Case Rep Oncol Med 2019, 2019: 7183747. PMID: 31781445, DOI: 10.1155/2019/7183747.Peer-Reviewed Case Reports and Technical NotesClinical characteristics and survival of lung cancer patients according to insurance status prior to and post implementation of the Affordable Care Act.
Matutino A, Pereira A, Kornaga E, Lopes G, Bebb D, Verma S. Clinical characteristics and survival of lung cancer patients according to insurance status prior to and post implementation of the Affordable Care Act. Journal Of Clinical Oncology 2018, 36: e18607-e18607. DOI: 10.1200/jco.2018.36.15_suppl.e18607.Peer-Reviewed Original Research
2018
40P Comparison of clinical characteristics and survival of lung cancer patients in a Canadian province and in the United States according to insurance status
Matutino A, Kornaga E, Dean M, Pereira A, Bebb G. 40P Comparison of clinical characteristics and survival of lung cancer patients in a Canadian province and in the United States according to insurance status. Journal Of Thoracic Oncology 2018, 13: s22-s23. DOI: 10.1016/s1556-0864(18)30320-4.Peer-Reviewed Original Research
2017
Prophylactic Cranial Irradiation for Extensive-Stage Small-Cell Lung Cancer: A Retrospective Analysis
Matutino A, Mak M, Takahashi T, Bitton R, Nakazato D, Fraile N, Guimarães R, Gabrielli F, Vasconcelos K, de A. Carvalho H, de Castro G. Prophylactic Cranial Irradiation for Extensive-Stage Small-Cell Lung Cancer: A Retrospective Analysis. Journal Of Global Oncology 2017, 4: jgo.17.00059. PMID: 30241202, PMCID: PMC6181177, DOI: 10.1200/jgo.17.00059.Peer-Reviewed Original ResearchConceptsExtensive-stage small-cell lung cancerProphylactic cranial irradiationSmall cell lung cancerProgression-free survivalBrain metastasesOverall survivalCranial irradiationLung cancerBenefit of PCISymptomatic brain metastasesFirst-line settingSecond-line chemotherapyKaplan-Meier methodPlatinum-based chemotherapyCareful patient selectionBrain metastasis controlBaseline brainEligible patientsSystemic chemotherapyChemotherapy exposureProgressive diseasePatient selectionTherapeutic challengeDecreased incidencePatient survival
2016
Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community
Protásio B, Matutino A, Lage L, Santana I, Ramos R, Sabbaga J, Capareli F, Saragiotto D, Riechelmann R, Hoff P. Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community. Clinical Colorectal Cancer 2016, 16: 65-72. PMID: 27515842, DOI: 10.1016/j.clcc.2016.07.001.Peer-Reviewed Original ResearchConceptsStage III colorectal cancerColorectal cancerClinical trialsHigh riskResected stage III colorectal cancerLogistic regression multivariate analysisStage III CRC patientsDisease-free survivalPredictors of recurrenceRegression multivariate analysisAge 70 yearsLarge cancer centerAdjuvant chemotherapyAdjuvant oxaliplatinFit patientsNeurotoxicity gradeUrgent surgeryAdjuvant regimenAdverse eventsCohort studyCommunity patientsConsecutive patientsCRC patientsMedian agePrognostic factorsMetaplastic breast cancer: A single-institution experience.
Silva A, Linck R, Lima J, Matutino A, Silva S, Vicentini M, Felizola M, Gagliato D, Hoff P, Mano M. Metaplastic breast cancer: A single-institution experience. Journal Of Clinical Oncology 2016, 34: e12575-e12575. DOI: 10.1200/jco.2016.34.15_suppl.e12575.Peer-Reviewed Original Research
2015
Successful Intravascular Correction of Intratumoral Pseudoaneurysm by Erosion of the Aorta in a Patient with Thoracic Giant Cell Tumor of Bone Responding to Denosumab
Fraile N, Toloi D, Kurimori C, Matutino A, Codima A, Camargo V, Feher O, Munhoz R. Successful Intravascular Correction of Intratumoral Pseudoaneurysm by Erosion of the Aorta in a Patient with Thoracic Giant Cell Tumor of Bone Responding to Denosumab. Case Reports In Oncological Medicine 2015, 2015: 626741. PMID: 26600960, PMCID: PMC4639671, DOI: 10.1155/2015/626741.Peer-Reviewed Original ResearchGiant cell tumorCell tumorsGiant cellsOsteoclast-like giant cellsInitiation of denosumabNuclear factor-kB ligandUnequivocal clinical improvementTumor stromal cellsMonoclonal antibody denosumabAdvanced GCTMultiple resectionsUnremarkable recoveryClinical improvementFirst doseSurgical resectionEndovascular approachAggressive neoplasmTherapeutic optionsAntibody denosumabStent placementOsteoclast activityDenosumabReceptor activatorActionable targetsStromal cellsCâncer de mama: efeito prognóstico da resposta patológica completa após quimioterapia neoadjuvante
Vaisberg V, Vilas Boas M, Stephan B, Matutino A, Lima J, Mano M. Câncer de mama: efeito prognóstico da resposta patológica completa após quimioterapia neoadjuvante. Revista De Medicina 2015, 94: 31-31. DOI: 10.11606/issn.1679-9836.v94isupl.p31-31.Peer-Reviewed Original Research1958 Correlation between body mass index and pathologic complete response after neoadjuvant chemotherapy for locally advanced breast cancer
Lima J, Matutino A, Silva S, Silva-Junior A, Boas M, Stephan B, Van Vairsberg V, Pereira A, Barroso-Sousa R, Mano M. 1958 Correlation between body mass index and pathologic complete response after neoadjuvant chemotherapy for locally advanced breast cancer. European Journal Of Cancer 2015, 51: s319. DOI: 10.1016/s0959-8049(16)30906-6.Peer-Reviewed Original Research1959 Neoadjuvant chemotherapy for elderly breast cancer patients
Matutino A, Lima J, Silva S, Boas M, Stephan B, Van Vairsberg V, Fraile N, Barroso-Sousa R, Mano M. 1959 Neoadjuvant chemotherapy for elderly breast cancer patients. European Journal Of Cancer 2015, 51: s319. DOI: 10.1016/s0959-8049(16)30907-8.Peer-Reviewed Original Research